JPWO2019137971A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019137971A5 JPWO2019137971A5 JP2020538084A JP2020538084A JPWO2019137971A5 JP WO2019137971 A5 JPWO2019137971 A5 JP WO2019137971A5 JP 2020538084 A JP2020538084 A JP 2020538084A JP 2020538084 A JP2020538084 A JP 2020538084A JP WO2019137971 A5 JPWO2019137971 A5 JP WO2019137971A5
- Authority
- JP
- Japan
- Prior art keywords
- triazole
- deoxy
- thio
- galactopyranoside
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims 26
- 229910052736 halogen Inorganic materials 0.000 claims 17
- 150000002367 halogens Chemical class 0.000 claims 17
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 17
- -1 D-galactopyranose compound Chemical class 0.000 claims 16
- 150000001875 compounds Chemical class 0.000 claims 15
- 229910052739 hydrogen Inorganic materials 0.000 claims 13
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 10
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 230000033115 angiogenesis Effects 0.000 claims 8
- 229910052799 carbon Inorganic materials 0.000 claims 7
- 239000001257 hydrogen Substances 0.000 claims 7
- 206010016654 Fibrosis Diseases 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 230000004761 fibrosis Effects 0.000 claims 6
- 150000002431 hydrogen Chemical class 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 4
- 208000030159 metabolic disease Diseases 0.000 claims 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 102000000795 Galectin 1 Human genes 0.000 claims 2
- 108010001498 Galectin 1 Proteins 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 208000029523 Interstitial Lung disease Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 208000034038 Pathologic Neovascularization Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 206010039491 Sarcoma Diseases 0.000 claims 2
- 208000034189 Sclerosis Diseases 0.000 claims 2
- 206010040070 Septic Shock Diseases 0.000 claims 2
- 201000002661 Spondylitis Diseases 0.000 claims 2
- 206010042971 T-cell lymphoma Diseases 0.000 claims 2
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims 2
- 208000031737 Tissue Adhesions Diseases 0.000 claims 2
- 206010052779 Transplant rejections Diseases 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 230000002159 abnormal effect Effects 0.000 claims 2
- 230000001476 alcoholic effect Effects 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 229910052794 bromium Inorganic materials 0.000 claims 2
- 229910052801 chlorine Inorganic materials 0.000 claims 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims 2
- 201000000159 corneal neovascularization Diseases 0.000 claims 2
- 230000007850 degeneration Effects 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000030533 eye disease Diseases 0.000 claims 2
- 208000019622 heart disease Diseases 0.000 claims 2
- 208000006454 hepatitis Diseases 0.000 claims 2
- 231100000283 hepatitis Toxicity 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 208000026278 immune system disease Diseases 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- 208000019423 liver disease Diseases 0.000 claims 2
- 230000000938 luteal effect Effects 0.000 claims 2
- 208000037819 metastatic cancer Diseases 0.000 claims 2
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 201000002793 renal fibrosis Diseases 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 230000036573 scar formation Effects 0.000 claims 2
- 230000037390 scarring Effects 0.000 claims 2
- 230000036303 septic shock Effects 0.000 claims 2
- 208000017520 skin disease Diseases 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 230000009885 systemic effect Effects 0.000 claims 2
- 230000001256 tonic effect Effects 0.000 claims 2
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 claims 1
- DEMKNLXJQNYAFY-UHFFFAOYSA-N 5-chloro-2-methylpyridine Chemical compound CC1=CC=C(Cl)C=N1 DEMKNLXJQNYAFY-UHFFFAOYSA-N 0.000 claims 1
- BZSCLIZOYQVCKE-FFFICINHSA-N BrC=1N=C(SC=1)C=1N=NN(C=1)[C@@H]1[C@H]([C@@H](SC=2C=NC(=C(C=2)Br)C(F)(F)F)O[C@@H]([C@@H]1O)CO)O Chemical compound BrC=1N=C(SC=1)C=1N=NN(C=1)[C@@H]1[C@H]([C@@H](SC=2C=NC(=C(C=2)Br)C(F)(F)F)O[C@@H]([C@@H]1O)CO)O BZSCLIZOYQVCKE-FFFICINHSA-N 0.000 claims 1
- QFXZCDKRLMTLPM-DRRXZNNHSA-N CC1=C(Cl)C=C(S[C@H]2O[C@H](CO)[C@H](O)[C@@H]([C@H]2O)N2C=C(N=N2)C2=CSC(O)=N2)C=C1 Chemical compound CC1=C(Cl)C=C(S[C@H]2O[C@H](CO)[C@H](O)[C@@H]([C@H]2O)N2C=C(N=N2)C2=CSC(O)=N2)C=C1 QFXZCDKRLMTLPM-DRRXZNNHSA-N 0.000 claims 1
- WYESJSCHMLZEAD-OWKNBALPSA-N ClC=1N=C(SC=1)C=1N=NN(C=1)[C@@H]1[C@H]([C@@H](SC=2C(=NC=C(C=2)Br)C#N)O[C@@H]([C@@H]1O)CO)O Chemical compound ClC=1N=C(SC=1)C=1N=NN(C=1)[C@@H]1[C@H]([C@@H](SC=2C(=NC=C(C=2)Br)C#N)O[C@@H]([C@@H]1O)CO)O WYESJSCHMLZEAD-OWKNBALPSA-N 0.000 claims 1
- PRPUOSWXELEYOF-DMZMFVCCSA-N ClC=1N=C(SC=1)C=1N=NN(C=1)[C@@H]1[C@H]([C@@H](SC=2C(=NC=C(C=2)Br)C(C)C)O[C@@H]([C@@H]1O)CO)O Chemical compound ClC=1N=C(SC=1)C=1N=NN(C=1)[C@@H]1[C@H]([C@@H](SC=2C(=NC=C(C=2)Br)C(C)C)O[C@@H]([C@@H]1O)CO)O PRPUOSWXELEYOF-DMZMFVCCSA-N 0.000 claims 1
- JYBNMFQGALVNGD-OWKNBALPSA-N ClC=1N=C(SC=1)C=1N=NN(C=1)[C@@H]1[C@H]([C@@H](SC=2C(=NC=C(C=2)Cl)C#N)O[C@@H]([C@@H]1O)CO)O Chemical compound ClC=1N=C(SC=1)C=1N=NN(C=1)[C@@H]1[C@H]([C@@H](SC=2C(=NC=C(C=2)Cl)C#N)O[C@@H]([C@@H]1O)CO)O JYBNMFQGALVNGD-OWKNBALPSA-N 0.000 claims 1
- OXSNBWCOFLKQOE-FFFICINHSA-N ClC=1N=C(SC=1)C=1N=NN(C=1)[C@@H]1[C@H]([C@@H](SC=2C=NC(=C(C=2)Br)C(F)(F)F)O[C@@H]([C@@H]1O)CO)O Chemical compound ClC=1N=C(SC=1)C=1N=NN(C=1)[C@@H]1[C@H]([C@@H](SC=2C=NC(=C(C=2)Br)C(F)(F)F)O[C@@H]([C@@H]1O)CO)O OXSNBWCOFLKQOE-FFFICINHSA-N 0.000 claims 1
- RTGGHYKPRGSTFZ-YNIRGQLTSA-N ClC=1N=C(SC=1)C=1N=NN(C=1)[C@@H]1[C@H]([C@@H](SC=2C=NC(=C(C=2)Cl)C#N)O[C@@H]([C@@H]1O)CO)O Chemical compound ClC=1N=C(SC=1)C=1N=NN(C=1)[C@@H]1[C@H]([C@@H](SC=2C=NC(=C(C=2)Cl)C#N)O[C@@H]([C@@H]1O)CO)O RTGGHYKPRGSTFZ-YNIRGQLTSA-N 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- DMKYSPPFUVMAFM-DZQJYWQESA-N OC=1SC=C(N=1)C=1N=NN(C=1)[C@@H]1[C@H]([C@@H](SC=2C(=NC=C(C=2)Br)C#N)O[C@@H]([C@@H]1O)CO)O Chemical compound OC=1SC=C(N=1)C=1N=NN(C=1)[C@@H]1[C@H]([C@@H](SC=2C(=NC=C(C=2)Br)C#N)O[C@@H]([C@@H]1O)CO)O DMKYSPPFUVMAFM-DZQJYWQESA-N 0.000 claims 1
- GIOMSDNHTBESOT-LYYZXLFJSA-N OC=1SC=C(N=1)C=1N=NN(C=1)[C@@H]1[C@H]([C@@H](SC=2C=NC(=C(C=2)Cl)C#N)O[C@@H]([C@@H]1O)CO)O Chemical compound OC=1SC=C(N=1)C=1N=NN(C=1)[C@@H]1[C@H]([C@@H](SC=2C=NC(=C(C=2)Cl)C#N)O[C@@H]([C@@H]1O)CO)O GIOMSDNHTBESOT-LYYZXLFJSA-N 0.000 claims 1
- BIXUJZWHKMBPPF-DRRXZNNHSA-N OC[C@H]1O[C@H](SC2=CC(Br)=C(C=C2)C#N)[C@H](O)[C@H]([C@H]1O)N1C=C(N=N1)C1=CSC(O)=N1 Chemical compound OC[C@H]1O[C@H](SC2=CC(Br)=C(C=C2)C#N)[C@H](O)[C@H]([C@H]1O)N1C=C(N=N1)C1=CSC(O)=N1 BIXUJZWHKMBPPF-DRRXZNNHSA-N 0.000 claims 1
- DEZXUKFQGWEBPA-DZQJYWQESA-N OC[C@H]1O[C@H](SC2=CC(Br)=C(F)C(Br)=C2)[C@H](O)[C@H]([C@H]1O)N1C=C(N=N1)C1=CSC(O)=N1 Chemical compound OC[C@H]1O[C@H](SC2=CC(Br)=C(F)C(Br)=C2)[C@H](O)[C@H]([C@H]1O)N1C=C(N=N1)C1=CSC(O)=N1 DEZXUKFQGWEBPA-DZQJYWQESA-N 0.000 claims 1
- NABQCTZBPFTOGB-LYYZXLFJSA-N OC[C@H]1O[C@H](SC2=CC(Br)=C(N=C2)C#N)[C@H](O)[C@H]([C@H]1O)N1C=C(N=N1)C1=CSC(O)=N1 Chemical compound OC[C@H]1O[C@H](SC2=CC(Br)=C(N=C2)C#N)[C@H](O)[C@H]([C@H]1O)N1C=C(N=N1)C1=CSC(O)=N1 NABQCTZBPFTOGB-LYYZXLFJSA-N 0.000 claims 1
- CXCUPEGHBWIEBH-YNIRGQLTSA-N OC[C@H]1O[C@H](SC2=CC(Br)=C(N=C2)C#N)[C@H](O)[C@H]([C@H]1O)N1C=C(N=N1)C1=NC(Cl)=CS1 Chemical compound OC[C@H]1O[C@H](SC2=CC(Br)=C(N=C2)C#N)[C@H](O)[C@H]([C@H]1O)N1C=C(N=N1)C1=NC(Cl)=CS1 CXCUPEGHBWIEBH-YNIRGQLTSA-N 0.000 claims 1
- UCUUGPSLUNOFHQ-NLRWUALESA-N OC[C@H]1O[C@H](SC2=CC(Br)=C(N=C2)C(F)(F)F)[C@H](O)[C@H]([C@H]1O)N1C=C(N=N1)C1=CSC(O)=N1 Chemical compound OC[C@H]1O[C@H](SC2=CC(Br)=C(N=C2)C(F)(F)F)[C@H](O)[C@H]([C@H]1O)N1C=C(N=N1)C1=CSC(O)=N1 UCUUGPSLUNOFHQ-NLRWUALESA-N 0.000 claims 1
- INGORPMDIARWLA-SKVYFBIASA-N OC[C@H]1O[C@H](SC2=CC(Br)=C(N=C2)C(F)(F)F)[C@H](O)[C@H]([C@H]1O)N1C=C(N=N1)C1=NC(Cl)=C(Cl)S1 Chemical compound OC[C@H]1O[C@H](SC2=CC(Br)=C(N=C2)C(F)(F)F)[C@H](O)[C@H]([C@H]1O)N1C=C(N=N1)C1=NC(Cl)=C(Cl)S1 INGORPMDIARWLA-SKVYFBIASA-N 0.000 claims 1
- OZTRWWYTGPWGQL-LYYZXLFJSA-N OC[C@H]1O[C@H](SC2=CC(Cl)=C(C=C2)C(F)(F)F)[C@H](O)[C@H]([C@H]1O)N1C=C(N=N1)C1=CSC(O)=N1 Chemical compound OC[C@H]1O[C@H](SC2=CC(Cl)=C(C=C2)C(F)(F)F)[C@H](O)[C@H]([C@H]1O)N1C=C(N=N1)C1=CSC(O)=N1 OZTRWWYTGPWGQL-LYYZXLFJSA-N 0.000 claims 1
- GAHICCQTWURYKS-DZQJYWQESA-N OC[C@H]1O[C@H](SC2=CC(Cl)=C(F)C(Cl)=C2)[C@H](O)[C@H]([C@H]1O)N1C=C(N=N1)C1=CSC(O)=N1 Chemical compound OC[C@H]1O[C@H](SC2=CC(Cl)=C(F)C(Cl)=C2)[C@H](O)[C@H]([C@H]1O)N1C=C(N=N1)C1=CSC(O)=N1 GAHICCQTWURYKS-DZQJYWQESA-N 0.000 claims 1
- ANXOSUXMRNWBKV-NLRWUALESA-N OC[C@H]1O[C@H](SC2=CC(Cl)=C(N=C2)C(F)(F)F)[C@H](O)[C@H]([C@H]1O)N1C=C(N=N1)C1=CSC(O)=N1 Chemical compound OC[C@H]1O[C@H](SC2=CC(Cl)=C(N=C2)C(F)(F)F)[C@H](O)[C@H]([C@H]1O)N1C=C(N=N1)C1=CSC(O)=N1 ANXOSUXMRNWBKV-NLRWUALESA-N 0.000 claims 1
- WTMKWTUCQLAPLG-DZQJYWQESA-N OC[C@H]1O[C@H](SC2=CC(Cl)=C(SC(F)(F)F)C=C2)[C@H](O)[C@H]([C@H]1O)N1C=C(N=N1)C1=CSC(O)=N1 Chemical compound OC[C@H]1O[C@H](SC2=CC(Cl)=C(SC(F)(F)F)C=C2)[C@H](O)[C@H]([C@H]1O)N1C=C(N=N1)C1=CSC(O)=N1 WTMKWTUCQLAPLG-DZQJYWQESA-N 0.000 claims 1
- XDMSEZKGPZZNKV-DZQJYWQESA-N OC[C@H]1O[C@H](SC2=CC(Cl)=CN=C2C#N)[C@H](O)[C@H]([C@H]1O)N1C=C(N=N1)C1=CSC(O)=N1 Chemical compound OC[C@H]1O[C@H](SC2=CC(Cl)=CN=C2C#N)[C@H](O)[C@H]([C@H]1O)N1C=C(N=N1)C1=CSC(O)=N1 XDMSEZKGPZZNKV-DZQJYWQESA-N 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims 1
- GZCGUPFRVQAUEE-UHFFFAOYSA-N alpha-D-galactose Natural products OCC(O)C(O)C(O)C(O)C=O GZCGUPFRVQAUEE-UHFFFAOYSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-UHFFFAOYSA-N alpha-D-glucopyranose Natural products OCC1OC(O)C(O)C(O)C1O WQZGKKKJIJFFOK-UHFFFAOYSA-N 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 229960003082 galactose Drugs 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 150000003214 pyranose derivatives Chemical group 0.000 claims 1
- 150000003852 triazoles Chemical group 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18150959.7 | 2018-01-10 | ||
| EP18150959 | 2018-01-10 | ||
| PCT/EP2019/050467 WO2019137971A1 (en) | 2018-01-10 | 2019-01-09 | Novel galactoside inhibitor of galectins |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021510692A JP2021510692A (ja) | 2021-04-30 |
| JP2021510692A5 JP2021510692A5 (https=) | 2022-01-13 |
| JPWO2019137971A5 true JPWO2019137971A5 (https=) | 2022-01-13 |
Family
ID=60953765
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020538084A Pending JP2021510692A (ja) | 2018-01-10 | 2019-01-09 | ガレクチンの新規なガラクトシド阻害剤 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11046725B2 (https=) |
| EP (1) | EP3737686A1 (https=) |
| JP (1) | JP2021510692A (https=) |
| KR (1) | KR20200108303A (https=) |
| CN (1) | CN111699193A (https=) |
| BR (1) | BR112020013647A2 (https=) |
| CA (1) | CA3086092A1 (https=) |
| EA (1) | EA202091684A1 (https=) |
| MX (1) | MX2020007391A (https=) |
| WO (1) | WO2019137971A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6904906B2 (ja) * | 2015-01-30 | 2021-07-21 | ガレクト・バイオテック・エイビイ | ガレクチンの新規なガラクトシド阻害剤 |
| US11046725B2 (en) * | 2018-01-10 | 2021-06-29 | Galecto Biotech Ab | Galactoside inhibitor of galectins |
| CN113366007A (zh) * | 2018-10-15 | 2021-09-07 | 格莱克特生物技术公司 | 半乳糖凝集素的半乳糖苷抑制剂 |
| EP3983423A4 (en) | 2019-06-14 | 2023-07-19 | Université Laval | SYNTHESIS OF 3-AZIDO-3-DEOXY-D-GALACTOPYRANOSE |
| CA3141436A1 (en) * | 2019-07-03 | 2021-01-07 | Fredrik Zetterberg | Novel galactoside inhibitor of galectins |
| TW202134214A (zh) * | 2020-03-04 | 2021-09-16 | 瑞士商先正達農作物保護公司 | 用於製備具有3-含硫取代基的5-氯-吡啶-2-甲酸醯胺以及甲酸鹽之方法 |
| WO2025180907A1 (en) * | 2024-02-26 | 2025-09-04 | Galecto Biotech Ab | Specific galactoside inhibitor of galectin-1 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6849607B2 (en) | 2001-05-09 | 2005-02-01 | Health Research, Inc. | Galectin recognized photosensitizers for photodynamic therapy |
| SE0401301D0 (sv) | 2004-05-21 | 2004-05-21 | Forskarpatent I Syd Ab | Novel 3-triazolyl-galactoside inhibitors of galectins |
| SE0401300D0 (sv) | 2004-05-21 | 2004-05-21 | Forskarpatent I Syd Ab | Novel Galactoside Inhibitors of Galectins |
| CN102439021B (zh) | 2009-04-28 | 2015-09-02 | 格莱克特生物技术公司 | 半乳凝素的新型半乳糖苷抑制剂 |
| US8828971B2 (en) | 2012-10-10 | 2014-09-09 | Galectin Therapeutics, Inc. | Galactose-pronged carbohydrate compounds for the treatment of diabetic nephropathy and associated disorders |
| JP2015535233A (ja) | 2012-10-31 | 2015-12-10 | ガレクト・バイオテック・エイビイ | ガレクチン−３のガラクトシド阻害剤及び肺線維症のためのその使用 |
| EP3245216B1 (en) * | 2015-01-16 | 2019-12-11 | Galecto Biotech AB | Novel galactoside inhibitor of galectins |
| JP6904906B2 (ja) * | 2015-01-30 | 2021-07-21 | ガレクト・バイオテック・エイビイ | ガレクチンの新規なガラクトシド阻害剤 |
| CA3025867A1 (en) * | 2016-07-12 | 2018-01-18 | Galecto Biotech Ab | Alpha-d-galactoside inhibitors of galectins |
| WO2018011093A1 (en) * | 2016-07-12 | 2018-01-18 | Galecto Biotech Ab | Alpha-d-galactoside inhibitors of galectins |
| US11046725B2 (en) * | 2018-01-10 | 2021-06-29 | Galecto Biotech Ab | Galactoside inhibitor of galectins |
-
2019
- 2019-01-09 US US16/960,996 patent/US11046725B2/en active Active
- 2019-01-09 CN CN201980007910.3A patent/CN111699193A/zh active Pending
- 2019-01-09 JP JP2020538084A patent/JP2021510692A/ja active Pending
- 2019-01-09 EA EA202091684A patent/EA202091684A1/ru unknown
- 2019-01-09 MX MX2020007391A patent/MX2020007391A/es unknown
- 2019-01-09 KR KR1020207022591A patent/KR20200108303A/ko not_active Withdrawn
- 2019-01-09 BR BR112020013647-6A patent/BR112020013647A2/pt not_active Application Discontinuation
- 2019-01-09 CA CA3086092A patent/CA3086092A1/en active Pending
- 2019-01-09 WO PCT/EP2019/050467 patent/WO2019137971A1/en not_active Ceased
- 2019-01-09 EP EP19700281.9A patent/EP3737686A1/en not_active Withdrawn
-
2021
- 2021-05-24 US US17/327,954 patent/US11827666B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021510692A5 (https=) | ||
| JP2019522007A5 (https=) | ||
| JP2019524720A5 (https=) | ||
| JP2024050527A5 (https=) | ||
| JP2019510787A5 (https=) | ||
| JP2019034943A5 (https=) | ||
| JP2013500314A5 (https=) | ||
| JP2018535967A5 (https=) | ||
| JP2012532112A5 (https=) | ||
| CA2718383A1 (en) | Heteroaryl-substituted dicyanopyridines and use thereof for treatment of cardiovascular diseases | |
| JP2015504909A5 (https=) | ||
| JP2018525425A5 (https=) | ||
| JP2002528493A5 (https=) | ||
| JP6672296B2 (ja) | 強力なγ−セクレターゼモジュレータ | |
| JP2019535723A5 (https=) | ||
| JP2019500315A5 (https=) | ||
| JPWO2019137971A5 (https=) | ||
| JP2006513221A5 (https=) | ||
| JP2010506919A5 (https=) | ||
| JP2024045685A (ja) | 結晶 | |
| TWI555744B (zh) | Novel EP4 agonists | |
| JP2009515951A5 (https=) | ||
| JP2014502273A (ja) | スフィンゴシン−１−リン酸（ｓ１ｐ）受容体モジュレーターとしての新規ベンジルアゼチジン誘導体 | |
| JP2010534670A5 (https=) | ||
| JPWO2023016529A5 (https=) |